Rebecca Elliott

Rebecca Elliott

Auto-generated profile, based on publicly available information

Rebecca Elliott

BioAnalytical Sciences, Genentech, Inc, South San Francisco, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2016 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
JRJane Ruppel
Jane Ruppel
ABAnn Brady
Ann Brady
RERebecca Elliott
Rebecca Elliott
CLCecilia Leddy
Cecilia Leddy
MPMarco Palencia
Marco Palencia
EWEric Wakshull
Eric Wakshull
Anti-therapeutic antibodies (ATAs) may impact drug exposure and activity and induce immune complex mediated toxicity; therefore the accurate measurement of ATA is important for the analysis of drug safety and efficacy. Preexisting ATAs to the hinge region of anti-Delta like ligand 4 (anti-DLL4) F(ab′)2, a potential antitumor therapeutic, were detected in cynomolgus monkey serum, which presented a challenge in developing assays for detecting treatment induced ATA. A total ATA assay was developed using a bridging ELISA that detected both anti-CDR and anti-framework ATA including anti-hinge reactivity. A competition assay that could detect 500 ng/mL of anti-CDR ATA in the presence of preexisting ATA was also developed to determine ATA specific to the anti-DLL4 F(ab′)2CDR using anti-DLL4 F(ab′)2and a control F(ab′)2. We used these assay methods in a cynomolgus monkey in vivo study to successfully evaluate total and anti-CDR ATA. The preexisting anti-hinge reactivity was also observed to a lesser extent in human serum, and a similar approach could be applied for specific immunogenicity assessment in clinical trials.

19 December 2024 in The AAPS Journal
Verified
Journal Article
Open access
PDF file
RER. J. Elliott
R. J. Elliott
TPT. Pourmohamad
T. Pourmohamad
YWY. Webb-Vargas
Y. Webb-Vargas
WYW. Yan
W. Yan
INI. Nijem
I. Nijem
YSY. Song
Y. Song
Per FDA guidance, method comparability should be established if an anti-drug antibody (ADA) assay is run by two or more independent laboratories during a study. Genentech, Inc. is evaluating an immunogenicity risk-based comparability approach consisting of both technical and clinical aspects. Technical comparability of the relative sensitivity (RS) is assessed using the Two One-Sided T-tests (TOST) statistical analysis which evaluates if the difference (in absolute value) of the RS means of the two laboratories is less than a pre-specified level of comparability, the practically significant difference (PSD). Clinical comparability is based on the molecule’s immunogenicity risk. A basic and in-depth assessment for low and high-risk molecules are used, respectively. An alternative strategy for molecules with limited incurred sample availability is to be used. In the basic assessment, samples are either unfortified or fortified with surrogate ADA positive control at method appropriate concentrations in a representative biological matrix. Acceptable comparability requires in both methods i) at least 80% of the unfortified samples screen and confirm negative, ii) at least 90% of the low concentration samples screen and confirm positive; and iii) 100% of the high concentration samples screen and confirm positive. The in-depth assessment uses at least 100 incurred samples from 30 or more ADA-positive and ADA-negative patients. The results are evaluated using a 2 by 2-confusion matrix and Cohen’s Kappa score where 1 indicates perfect agreement. Acceptable comparability requires a Cohen’s Kappa score of greater than 0.40. This strategy allows for a robust technical and clinical method comparability assessment. Graphical Abstract

9 November 2026 in The AAPS Journal
Verified
Journal Article
Closed access
MMMauricio Maia
Mauricio Maia
RERebecca Elliott
Rebecca Elliott
WYWeili Yan
Weili Yan
JBJochen Brumm
Jochen Brumm